Physician profile
Rajindar Sikand
NPI 1427035773
$4,592.02
in general payments reported to CMS, 2019-2025
33 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $90.24 · 2021: $367 · 2022: $897 · 2023: $1,043 · 2024: $756 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $750.67 | 2019-2025 | Airsupra, Breztri, Symbicort |
| Grifols USA, LLC | $567.68 | 2019-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $531.73 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.85 | 2019-2025 | Ofev, Jardiance, Stiolto Respimat |
| Mylan Specialty L.P. | $343.59 | 2019-2024 | Yupelri, Yupelri |
| Inogen, INC. | $335.01 | 2022-2025 | Inogen |
| Takeda Pharmaceuticals U.S.A., INC. | $209.16 | 2022-2025 | Glassia |
| Pulmonx Corporation | $193.36 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $182.11 | 2022-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $151.35 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $112.22 | 2023-2024 | Cologuard Collection Kit |
| Insmed, INC. | $101.95 | 2025 | Brinsupri, Arikayce |
| Sunovion Pharmaceuticals INC. | $69.17 | 2019 | |
| Circassia INC. | $55.22 | 2019 | |
| Boston Scientific Corporation | $47.44 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $47.11 | 2020-2021 | |
| Janssen Biotech, INC. | $45.51 | 2023-2024 | Stelara |
| Electromed, INC. | $43.62 | 2022 | |
| Edwards Lifesciences Corporation | $38.61 | 2019-2021 | |
| Ethicon INC. | $37.54 | 2024 | Monarch Platform |
| Verona Pharma, INC. | $32.43 | 2025 | Ohtuvayre |
| Dexcom, INC. | $31.54 | 2023 | Dexcom G6 Transmitter |
| Covis Pharma Gmbh | $29.81 | 2022 | |
| Merck Sharp & Dohme LLC | $27.39 | 2025 | Verquvo |
| Phathom Pharmaceuticals, INC. | $25.62 | 2024 | Voquezna |
| Resmed Corp | $24.18 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.18 | 2023 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.39 | 2022 | |
| Adma Biomanufacturing LLC | $16.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.85 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.49 | 2019 | |
| Novo Nordisk INC | $14.97 | 2025 | Wegovy |
| Teleflex LLC | $13.11 | 2023 | Turnpike |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajindar Sikand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.